By Pierre Hainaut, Klas G. Wiman
The invention of p53 in 1979 marks the start of a so much attention-grabbing period of contemporary melanoma learn and molecular biology, an period that continues to be in complete swing and doesn't express any indicators of finishing within the foreseeable destiny. p53 has emerged as a key tumor suppressor and demanding aim for novel melanoma treatment. For round 10 years, p53 used to be thought of an oncogene with slightly strange gains. even though, a big paradigm shift happened round 1988-89 while fascinating new findings tested that ordinary (wild kind) p53 may well inhibit transformation of cells in tradition and that the p53 gene used to be mutated in a wide fraction of human tumors. in truth, p53 the main usually mutated gene in melanoma cells. next paintings throughout the 1990’s confirmed that p53 was once a transcription issue that regulates many different genes, and that p53 can set off apoptosis, the suicide software of the telephone. This booklet, written by means of world-leading p53 researchers together with lots of those that have formed the sector during the last 25 years, presents specified insights into the growth of the p53 box and the clients for larger melanoma prognosis and remedy sooner or later. it's going to be of curiosity to every person operating in melanoma learn, scientific oncology, and molecular biology, and certainly to anyone attracted to technological know-how, medication, in addition to in contemporary advancements of the information and ideas of the molecular biology of melanoma.
Read Online or Download 25 Years of P53 Research PDF
Similar immunology books
Univ. of Liverpool, united kingdom. Compiles numerous protocols for manipulating RNA molecules and for inactivating gene expression in vivo. For pros. sixty one members, 39 U. S. DNLM: RNA, Catalytic.
Stephen P Robinson, MD, PhD, and Andrew Stagg, PhD, have introduced jointly a variety of time-proven tools for learning those dendritic cells. a lot of those simply reproducible thoughts care for the matter of acquiring enough dendritic cells for research, even if via isolation from a large vareity of tissues, or from a variety of progenitor mobile populations.
New proof at the origins and therapy of continual fatigue syndrome! Written through one of many top specialists within the box, power Fatigue Syndrome and the physique? s Immune security method provides very important new info on a crippling disease that has the biomedical group trying to find solutions. present study indicates CFS is linked to immune abnormalities which can in all likelihood account for its beginning and improvement.
- Continuum Mechanics Mase
- Schaum's outline of theory and problems of immunology
- Handbook of transcription factor NF-kappaB
- Acute Coronary Syndromes, Third Edition
- Mucosal Immunology of Acute Bacterial Pneumonia
Additional resources for 25 Years of P53 Research
DeOme K. Formal discussion of: multiple factors in mouse mammary tumorigenesis. Cancer Research, 1965. 25: 1348-1351. J. p53 gain of function mutations. Nature Genetics, 1993. 4: 42-46. , Eckstein J. Cdc25 protein phosphatases in cell proliferation. Biochim. , 1997. 1332: M53-M63. , Uphoff C. p53 alterations in human leukemia-lymphoma cell lines: in vitro artifact or prerequisite for cell immortalization? Leukemia, 2000. 14: 198-206. , Vogelstein B. Definition of a consensus binding site for p53.
Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene, 2000. 19: 1256. D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science, 1998. 281: 1677-1679. P. Crystal structure of a p53 tumor suppressorDNA complex: understanding tumorigenic mutations. Science, 1994. 265: 334-335. , Lamb P. The cellular protein p53 in human tumors. Mol. Biol. , 1984. 2: 261-272. M. SV40 large tumor antigen forma a specific complex with the product of the retinoblastoma susceptibility gene.
4: p. 1689-1694. B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proceedings of the National Academy of Sciences USA, 2001. 98: 11598-11603. B. The biological basis of cancer. 1998; University of Cambridge Press. Miller R. Gerontology as oncology. Research on aging as the key to the understanding of cancer. Cancer, 1991. 68: 2496-2501. , The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.